Anti-tumor effects of anti-programmed cell death-1 antibody treatment are attenuated in streptozotocin-induced diabetic mice

[1]  A. Allen,et al.  The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer , 2021, Oncology.

[2]  B. Nkambule,et al.  A systematic review and meta-analysis on the regulation of programmed cell death-1 on T-cells in type 2 diabetes , 2021, Medicine.

[3]  F. Yoshikawa,et al.  Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan , 2021, Diabetes, metabolic syndrome and obesity : targets and therapy.

[4]  Bo Zhong,et al.  CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer , 2020, Nature Communications.

[5]  R. Holt,et al.  Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy , 2020, Frontiers in Immunology.

[6]  M. Akiyama,et al.  Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study , 2020, Journal for ImmunoTherapy of Cancer.

[7]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[8]  R. Poppiti,et al.  Diabetes mellitus type 2 is associated with increased tumor expression of programmed death-ligand 1 (PD-L1) in surgically resected non-small cell lung cancer-A matched case-control study. , 2020, Cancer treatment and research communications.

[9]  G. Hitman,et al.  Type 2 diabetes is associated with the accumulation of senescent T cells , 2019, Clinical and experimental immunology.

[10]  A. Imagawa,et al.  Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. , 2019, Endocrine journal.

[11]  G. Freeman,et al.  Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. , 2019, Immunity.

[12]  D. Jackson,et al.  Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. , 2019, Cancer cell.

[13]  P. Kuppen,et al.  Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features , 2018, Journal of cellular physiology.

[14]  A. Kengne,et al.  T-cell Activation And Dysfunction in Hyperglycaemia , 2018 .

[15]  Zhengming Chen,et al.  Diabetes, plasma glucose and incidence of colorectal cancer in Chinese adults: a prospective study of 0.5 million people , 2018, Journal of Epidemiology & Community Health.

[16]  Masahide Takahashi,et al.  Critical role of rabphilin‐3A in the pathophysiology of experimental lymphocytic neurohypophysitis , 2018, The Journal of pathology.

[17]  G. Coukos,et al.  Mechanisms regulating T-cell infiltration and activity in solid tumors. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Freeman,et al.  PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity , 2017, The Journal of experimental medicine.

[19]  Y. Oshida,et al.  Anti-pituitary antibodies against corticotrophs in IgG4-related hypophysitis , 2017, Pituitary.

[20]  A. Korman,et al.  Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology , 2016, PloS one.

[21]  Shari Pilon-Thomas,et al.  Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy , 2016, PloS one.

[22]  C. Liu,et al.  A Linear Dose-Response Relationship between Fasting Plasma Glucose and Colorectal Cancer Risk: Systematic Review and Meta-analysis , 2015, Scientific Reports.

[23]  Pei-yu Chang,et al.  Defects in the Acquisition of Tumor-Killing Capability of CD8+ Cytotoxic T Cells in Streptozotocin-Induced Diabetic Mice , 2014, PloS one.

[24]  Yang Liu.  A VISTA on PD-1H. , 2014, The Journal of clinical investigation.

[25]  J. Wolchok,et al.  Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody , 2014, Science Translational Medicine.

[26]  J. Bishop,et al.  Hürthle cells predict hypothyroidism in interferon-γ transgenic mice of different genetic backgrounds. , 2012, Endocrinology.

[27]  U. V. von Andrian,et al.  Chemokine Guidance of Central Memory T Cells Is Critical for Antiviral Recall Responses in Lymph Nodes , 2012, Cell.

[28]  V. Serre-Beinier,et al.  Immunosuppressive Effects of Streptozotocin-Induced Diabetes Result in Absolute Lymphopenia and a Relative Increase of T Regulatory Cells , 2011, Diabetes.

[29]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[30]  M. Gonen,et al.  T Cell Infiltrate Predicts Long-Term Survival Following Resection of Colorectal Cancer Liver Metastases , 2009, Annals of Surgical Oncology.

[31]  M. Murray,et al.  Diabetes Mellitus Increases the Risk of Active Tuberculosis: A Systematic Review of 13 Observational Studies , 2008, PLoS medicine.

[32]  G. Leung,et al.  Diabetic control and risk of tuberculosis: a cohort study. , 2008, American journal of epidemiology.

[33]  C. Scavone,et al.  Neutrophil function and metabolism in individuals with diabetes mellitus. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[34]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[35]  T. Pawełczyk,et al.  Diabetes‐induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes , 2006, Immunology.

[36]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[37]  Guan-Cheng Li,et al.  Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis. , 2002, World journal of gastroenterology.

[38]  E. Bröcker,et al.  Strong expression of the lymphoattractant C‐X‐C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma , 1999, The Journal of pathology.

[39]  C. Garlanda,et al.  Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. , 1998, Journal of immunology.

[40]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[41]  L. Koniaris,et al.  Human Mig chemokine: biochemical and functional characterization , 1995, The Journal of experimental medicine.

[42]  J. Beckstead,et al.  A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.